Does Blue Cross Blue Shield of Minnesota Cover Ozempic?

What Ozempic Is and Why Formulary Placement Matters

Ozempic is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist containing semaglutide, manufactured by Novo Nordisk. The FDA approved it in December 2017 specifically for improving glycemic control in adults with type 2 diabetes and, later, for reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. [1]

That approval scope matters enormously for insurance purposes. Because Ozempic carries no FDA obesity label, plans that exclude weight-loss drugs under their benefit design can deny it even when a prescriber writes it for a patient with a BMI <30. The drug with the obesity indication is Wegovy, which contains the same molecule at a higher 2.4 mg maintenance dose. [2]

How GLP-1 Drugs Are Categorized on Formularies

Most commercial insurers, including BCBS Minnesota, organize drugs into tiers. Tier 1 drugs (generics) typically carry a $5 to $20 copay. Tier 3 or Tier 4 specialty drugs like Ozempic often carry 20 to 33 percent coinsurance or a flat copay of $100 or more per fill. The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9 percent mean weight loss at 68 weeks versus 2.4 percent with placebo, which accelerated insurer demand-management strategies for the entire semaglutide class. [3]

The Difference Between Ozempic and Wegovy for Coverage Purposes

Prescribers sometimes write Ozempic off-label for weight loss when Wegovy is unavailable or unaffordable. BCBS Minnesota plan documents routinely distinguish between the two. A plan that covers Wegovy through a separate obesity-management benefit may still deny Ozempic for that same purpose because the billing code and drug name differ. Ask your plan specifically about both drugs before assuming coverage transfers.

BCBS Minnesota Plan Types and How Each Handles Ozempic

BCBS Minnesota sells several distinct product lines, and Ozempic coverage rules differ across them.

Commercial Fully-Insured Plans (Individual and Small Group)

Fully-insured plans sold on MNsure or directly to small employers must follow Minnesota state benefit mandates. Minnesota does not currently mandate coverage of GLP-1 drugs for obesity, but state law does require coverage of diabetes treatments that meet accepted medical standards. [4] For a patient with a confirmed type 2 diabetes diagnosis (ICD-10 code E11.x), Ozempic coverage is generally available after prior authorization under these plans, usually on Tier 3.

Self-Funded Employer Plans (ERISA Plans)

Large employers in Minnesota often self-fund their health benefits under ERISA, meaning Minnesota state mandates do not apply. These employers design their own formularies. Some self-funded BCBS Minnesota plans exclude all GLP-1 drugs outright; others cover Ozempic for diabetes but carve out Wegovy entirely. You must read your Summary Plan Description (SPD) or call the member number on your insurance card to confirm.

Medicare Advantage Plans (Blue Cross Medicare Advantage)

Medicare Part D covered Ozempic for type 2 diabetes before the Inflation Reduction Act negotiations, and it remains covered under most Part D plans at negotiated rates. Blue Cross Medicare Advantage plans in Minnesota follow CMS formulary rules, which require coverage of at least two drugs per therapeutic category. Medicare does NOT cover weight-loss drugs under Part D (except in very limited circumstances added under the Treat and Reduce Obesity Act proposals still pending as of mid-2025). [5]

Medicaid (Blue Plus)

Blue Plus is BCBS Minnesota's Medicaid managed care product. Minnesota Medicaid's Preferred Drug List includes semaglutide products, but prior authorization criteria apply. As of 2025, Minnesota Medicaid covers Ozempic for type 2 diabetes when metformin or sulfonylureas have been tried or are contraindicated, aligning with the American Diabetes Association's 2024 Standards of Care. [6]

Prior Authorization Requirements for Ozempic Under BCBS Minnesota

Prior authorization (PA) is the single largest barrier most patients face. BCBS Minnesota's standard PA criteria for Ozempic in the diabetes indication typically require all of the following.

Typical PA Criteria

• A confirmed diagnosis of type 2 diabetes, not type 1.
• An HbA1c at or above a plan-specified threshold, often 7.5 percent or higher.
• Documentation that the patient has tried at least one or two preferred agents first, commonly metformin and a sulfonylurea or SGLT-2 inhibitor, depending on plan vintage.
• A prescribing provider who is an endocrinologist, primary care physician, or other appropriate specialist.
• Confirmation that the drug is being used for the FDA-approved indication, not off-label weight loss.

The ADA's 2024 Standards of Medical Care in Diabetes state: "For patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular benefit are recommended as part of the glucose-lowering regimen." [6] That guideline language can be quoted directly in a PA request letter to strengthen medical necessity.

What Your Prescriber Needs to Submit

Your provider's office must submit a PA request through BCBS Minnesota's online portal or by fax. The packet should include: office notes confirming the type 2 diabetes diagnosis, recent HbA1c lab values, a list of previously tried medications with dates and outcomes, and a letter of medical necessity. Turnaround time is typically 3 to 5 business days for standard reviews and 24 to 72 hours for urgent cases.

The HealthRX PA Readiness Checklist below summarizes what documentation to gather before your provider submits, reducing the most common rejection reasons:

1. Diabetes diagnosis confirmed in chart with ICD-10 code E11.x.
2. HbA1c result dated within the past 90 days.
3. Prior medication trial documented with start date, end date, and reason for discontinuation.
4. Cardiovascular risk factors or established ASCVD documented if applicable (strengthens medical necessity under LEADER and SUSTAIN-6 trial evidence).
5. Provider NPI and DEA numbers ready for the portal form.
6. Patient's plan ID and group number confirmed before submission.

What Happens When BCBS Minnesota Denies Ozempic Coverage

A denial is not the end of the road. Federal law under the ACA and ERISA gives you the right to appeal.

First-Level Internal Appeal

Submit a written appeal within 180 days of the denial notice (check your plan documents, as some plans allow less time). Include your provider's letter of medical necessity, copies of relevant lab work, and published clinical guidelines supporting Ozempic use. The LEADER trial (N=9,340) showed that liraglutide (a related GLP-1 agonist) reduced the rate of major adverse cardiovascular events by 13 percent versus placebo in high-risk type 2 diabetes patients, and the SUSTAIN-6 trial demonstrated semaglutide reduced the composite MACE endpoint by 26 percent. [7] Citing these outcomes in an appeal strengthens the argument that GLP-1 therapy is standard of care, not experimental.

External Independent Review

If BCBS Minnesota denies your internal appeal, you can request an external review by an independent review organization (IRO). In Minnesota, the Department of Commerce oversees this process. IRO decisions are binding on the insurer. Roughly 40 to 60 percent of external reviews in metabolic drug categories result in reversal, based on industry data from CMS appeals reports. [8]

Expedited Appeal for Urgent Situations

If your provider documents that waiting for a standard appeal timeline would seriously jeopardize your health (for example, rapid HbA1c deterioration or impending cardiovascular event), you can request an expedited review, which must be decided within 72 hours under federal rules.

Cost Options When Coverage Is Denied or Incomplete

Even with insurance, out-of-pocket costs for Ozempic can be substantial. Several options exist to reduce what you pay.

Novo Nordisk Instant Savings Card

Commercially insured patients who are not on a government program (Medicare, Medicaid, CHIP, or a federal employee plan) may use the Novo Nordisk Ozempic savings card. Eligible patients may pay as little as $25 per 1-month or $150 per 3-month prescription. The card does not apply to any government-funded plan, including Blue Plus (Medicaid). [9]

Patient Assistance Program (PAP)

Novo Nordisk's Patient Assistance Program provides Ozempic at no cost to uninsured or underinsured patients who meet income eligibility criteria, generally at or below 400 percent of the federal poverty level. Your provider's office can initiate the application at NovoCare.com.

90-Day Supply and Mail-Order Pharmacy

BCBS Minnesota often charges a lower effective per-day cost through mail-order (typically a 90-day supply for a 2-copay price). This does not reduce the tier placement but reduces total annual spending.

Compounded Semaglutide

The FDA placed semaglutide on its drug shortage list starting in 2022, which temporarily allowed state-licensed compounding pharmacies to produce semaglutide products. As of mid-2025, FDA has indicated Ozempic and Wegovy are no longer in shortage, meaning compounded semaglutide from 503B outsourcing facilities is no longer automatically permitted. [10] Compounded versions from 503A pharmacies for individual patients with a documented medical need may still be available in limited circumstances, but quality, potency, and sterility are not FDA-verified. BCBS Minnesota does not cover compounded semaglutide under any plan.

How Ozempic Coverage Compares to Other GLP-1 Drugs on the BCBS Minnesota Formulary

BCBS Minnesota's formulary typically includes several GLP-1 agents, and understanding tier differences can help you and your provider select the most cost-effective option if Ozempic is denied.

GLP-1 Formulary Comparison (Typical 2025 BCBS MN Commercial Tier Placement)

| Drug | Generic Name | FDA Indication | Typical Tier | PA Required | |---|---|---|---|---| | Ozempic 0.5/1/2 mg | semaglutide | Type 2 diabetes | Tier 3-4 | Yes | | Wegovy 2.4 mg | semaglutide | Obesity/overweight | Tier 4-5 or excluded | Yes | | Rybelsus 3/7/14 mg | oral semaglutide | Type 2 diabetes | Tier 3-4 | Yes | | Trulicity 1.5/3/4.5 mg | dulaglutide | Type 2 diabetes | Tier 2-3 (often preferred) | Sometimes | | Victoza 1.2/1.8 mg | liraglutide | Type 2 diabetes | Tier 3 | Yes | | Saxenda 3 mg | liraglutide | Obesity | Tier 4 or excluded | Yes |

Trulicity (dulaglutide) is frequently placed on a preferred tier because Eli Lilly negotiates favorable rebates with large insurers. If your primary goal is glycemic control and Ozempic's out-of-pocket cost is prohibitive, your provider may consider Trulicity as a formulary-preferred alternative while you appeal for Ozempic. The REWIND trial (N=9,901) showed dulaglutide reduced MACE by 12 percent versus placebo in patients with type 2 diabetes at cardiovascular risk, establishing its own outcomes credential. [11]

Oral Semaglutide (Rybelsus) as an Alternative

Rybelsus contains the same semaglutide molecule in a daily oral tablet. Some BCBS Minnesota plans tier it identically to Ozempic; others place it slightly lower because oral bioavailability is lower and it lacks the cardiovascular outcomes data of the injectable form at matched doses. For patients with needle aversion, asking your provider about Rybelsus is reasonable if injectable Ozempic is denied.

Steps to Take Right Now If You Need Ozempic Coverage

Work through this sequence to maximize your chances of getting Ozempic covered by BCBS Minnesota without a long delay.

Step 1. Confirm Your Plan's Current Formulary

Log in to the BCBS Minnesota member portal or call the pharmacy benefits number on your card. Ask specifically: "Is semaglutide injection (Ozempic) on my formulary, and what tier? What are the prior authorization criteria?" Get the answers in writing if possible, or note the representative's name and the date of the call.

Step 2. Have Your Provider Submit a Complete PA With Supporting Evidence

A PA that includes HbA1c values, prior medication history, cardiovascular risk documentation, and an explicit citation of ADA 2024 guidelines is more likely to be approved on first submission than a bare prescription request.

Step 3. Ask About a Bridge Supply

Some BCBS Minnesota plans and retail pharmacies allow a short-term emergency supply (typically 10 to 15 days) while a PA is pending, particularly for patients already established on Ozempic who are switching plans. Your pharmacy can request this under urgent supply provisions.

Step 4. File the Appeal Immediately If Denied

Do not wait. The denial letter will include a deadline. Missing that window forfeits your federal appeal rights for that denial. Your provider's office should co-sign the appeal letter, which carries more weight than a patient-only submission.

Step 5. Apply for Manufacturer Assistance in Parallel

Submit the Novo Nordisk savings card or PAP application at the same time as your appeal, so you have a cost path regardless of the appeal outcome.

What the Clinical Evidence Says About Why Ozempic Belongs in Type 2 Diabetes Treatment

Payers occasionally deny Ozempic on cost grounds disguised as clinical grounds. Knowing the evidence helps counter those arguments.

Cardiovascular Outcomes: SUSTAIN-6 and SUSTAIN-7

The SUSTAIN-6 trial (N=3,297) showed that semaglutide 0.5 mg and 1 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26 percent versus placebo (hazard ratio 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority) in patients with type 2 diabetes at high cardiovascular risk. [12] This outcome data supports medical necessity arguments specifically for patients with established ASCVD or multiple cardiovascular risk factors.

HbA1c Reduction: SUSTAIN-7

SUSTAIN-7 (N=1,201) compared semaglutide 0.5 mg and 1 mg to dulaglutide 0.75 mg and 1.5 mg. Semaglutide 1 mg reduced HbA1c by 1.8 percentage points versus 1.4 percentage points for dulaglutide 1.5 mg, and produced 6.5 kg greater weight reduction. [13] If a plan argues that a preferred agent (Trulicity) is equally effective, SUSTAIN-7 data directly refutes that claim for higher-baseline patients.

Kidney Outcomes: FLOW Trial

The FLOW trial (N=3,533) published in 2024 showed that semaglutide 1 mg reduced the risk of a composite kidney outcome by 24 percent versus placebo in patients with type 2 diabetes and chronic kidney disease. [14] For BCBS Minnesota members with diabetic nephropathy, citing FLOW adds a second medical necessity axis beyond glycemic control.

Frequently Asked Questions